By Chuck Stanley ( January 29, 2018, 4:16 PM EST) -- Novartis Pharmaceuticals Corp. on Friday urged the First Circuit to nix allegations it used a sham litigation to extend its monopoly over the leukemia drug Gleevec, saying a lower court correctly found a group of buyers had not shown the company's efforts to enforce the patent at issue were baseless....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.